Skip to main content

Search Videos

Showing 13 - 24 of 45 results

Previous| 1 | 2 | 3 ...4 |Next

Are there specific variants or clinical signatures of chronic cGVHD that respond better to ECP therapy than others? What other second line therapies, including ibrutinib, have been evaluated and/or FDA-approved?

Are there specific variants or clinical signatures of chronic cGVHD that respond better to ECP therapy than others? What other second line therapies, including ibrutinib, have been evaluated and/or FDA-approved?

Can you provide an overview of the clinical and pathologic findings of CTCL?

Can you provide an overview of the clinical and pathologic findings of CTCL?

What are the contraindications to ECP?

What are the contraindications to ECP?

How enduring is the response to ECP in appropriately selected patients with CTCL? What percentage of CTCL patients who have failed initial therapy can be expected to respond? And what are the characteristics of the dose-response curve?

How enduring is the response to ECP in appropriately selected patients with CTCL? What percentage of CTCL patients who have failed initial therapy can be expected to respond? And what are the characteristics of the dose-response curve?

What explains the bi-directional immunomodulatory and therapeutic effects of ECP, and what are the practical implications of its deployment against a broad spectrum of disease states?

What explains the bi-directional immunomodulatory and therapeutic effects of ECP, and what are the practical implications of its deployment against a broad spectrum of disease states?

Can you explain the importance of the fact that ECP provides dual or bifurcated effects on immune modulation, i.e., it can potentiate immune response against malignancies such as CTCL, and tolerize immune response in such conditions as GVHD?

Can you explain the importance of the fact that ECP provides dual or bifurcated effects on immune modulation, i.e., it can potentiate immune response against malignancies such as CTCL, and tolerize immune response in such conditions as GVHD?

Based on clinical trial data, the benefit-to-risk equation, contraindications, and experience with ECP at your institution, which patients with scleroderma are you treating with ECP, and what strategies are you deploying to optimize outcomes?

Based on clinical trial data, the benefit-to-risk equation, contraindications, and experience with ECP at your institution, which patients with scleroderma are you treating with ECP, and what strategies are you deploying to optimize outcomes?

Can you provide a brief review of scleroderma—systemic sclerosis—as a multisystem connective tissue disease characterized by humoral and cellular immune abnormalities and fibroblast activation?

Can you provide a brief review of scleroderma—systemic sclerosis—as a multisystem connective tissue disease characterized by humoral and cellular immune abnormalities and fibroblast activation?

What is the approach to using ECP in a patient with erythroderma, and when in the time course of the natural history of CTCL do these patients usually present to you for consideration of ECP?

What is the approach to using ECP in a patient with erythroderma, and when in the time course of the natural history of CTCL do these patients usually present to you for consideration of ECP?

What are the immunological criteria and/or clinical factors that must be met in order to identify patients with advanced CTCL who are likely to respond to ECP? Provide a systematic approach—including assessment of CD8 T-cell count—for screening?

What are the immunological criteria and/or clinical factors that must be met in order to identify patients with advanced CTCL who are likely to respond to ECP? Provide a systematic approach—including assessment of CD8 T-cell count—for screening?

Since you and others at Yale have treated a number of patients with scleroderma—and other conditions—with ECP, can you share your real world clinical experience with this treatment modality? And how measure clinical response to this therapy?

Since you and others at Yale have treated a number of patients with scleroderma—and other conditions—with ECP, can you share your real world clinical experience with this treatment modality? And how measure clinical response to this therapy?

What are the most important randomized studies that support ECP and what do we still need to know about ECP as a foundational, second-line treatment strategy for GVHD?

What are the most important randomized studies that support ECP and what do we still need to know about ECP as a foundational, second-line treatment strategy for GVHD?

Showing 13 - 24 of 45 results

Previous| 1 | 2 | 3 ...4 |Next